Navigation Links
A new anti diabetic drug on the anvil

India leads the top 10 countries estimated to have the highest number of diabetics in 2000 and 2030, with China and the US following closely. Type II Diabetes, one of the most common chronic diseases globally, is fast gaining // epidemic proportions throughout the world, with pathological manifestations including obesity, hypertension, hyperlipidemia and cardiovascular diseases. Since diabetes causes significant morbidity and mortality due to long-term micro and macro vascular complications, new drugs are required to combat it.

Glenmark Pharmaceuticals has recently filed for Phase I clinical trials for GRC 8200, its leading DPP-IV inhibitor compound, with the Medicines and Healthcare Products Regulatory Agency [MHRA] in the U.K. The dipeptidylpeptidase IV [DPP-IV] target is associated with glucose dependent insulin secretion and peripheral insulin resistance. While no DPP-IV inhibitor has been approved for marketing till date, among the scientific community DPP-IV inhibitors are expected to offer significant potential for being the therapy of choice, once approved.

The Phase I study will be conducted by Parexel U.K., a leading global CRO. The Phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bioavailability of GRC 8200 in humans. Pre-clinical studies have demonstrated GRC 8200 to be many times more potent than competing DPP-IV inhibitors. The compound is highly bioavailable and safe, displaying significant reduction in glucose excursion on oral glucose challenge. Pre-clinical studies have also demonstrated that GRC 8200 has the potential of being a long-acting compound with high selectivity to the DPP-IV target over DPP-II, VIII and IX.

Glenn Saldanha, Managing Director and CEO of Glenmark, states “We have a very aggressive timeline and hope to be the fourth to market with GRC 8200 in the DPP-IV class. We expect GRC 8200 to be launched on the US market in 2010.”

Related medicine news :

1. Gastrointestinal ills more common in diabetics
2. Pollution- hazardous for diabetics
3. New treatment for diabetics
4. Breast screening among diabetic women
5. Needle free future for diabetics
6. Care for footwear not required diabetic patients
7. Nightlights could ward diabetic blindness
8. Gene variant foretells diabetic neuropathy
9. Protein in diabetic neuropathy treatment
10. New target for antidiabetic agents identified
11. Study links diabetics to increased risk of urinary tract infections
Post Your Comments:

(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology: